Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin

PURPOSE: To identify effective metabolicinhibitors to suppress the aggressive growth of pancreatic ductal adenocarcinoma (PDAC), we explored the in vivo antitumor efficacy of metabolic inhibitors, as single agents, in a panel of patient-derived PDAC xenograft models (PDX) and investigated whether ge...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Cancer Res
Main Authors: Rajeshkumar, N.V., Yabuuchi, Shinichi, Pai, Shweta G., De Oliveira, Elizabeth, Kamphorst, Jurre J., Rabinowitz, Joshua D., Tejero, Héctor, Al-Shahrour, Fátima, Hidalgo, Manuel, Maitra, Anirban, Dang, Chi V.
Format: Artigo
Jezik:Inglês
Izdano: 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6540110/
https://ncbi.nlm.nih.gov/pubmed/28611197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1115
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki